移植
神经保护
旁分泌信号
医学
球体
间充质干细胞
再生(生物学)
细胞
细胞外基质
癌症研究
冲程(发动机)
神经科学
药理学
细胞生物学
病理
外科
内科学
生物
细胞培养
受体
工程类
机械工程
遗传学
作者
Ting-Wei Hsu,Yu‐Jen Lu,Yujie Lin,Yu‐Ting Huang,Li‐Hung Hsieh,Bing-Huan Wu,Yu‐Chun Lin,Li-Chi Chen,Hsin‐Wen Wang,Jui-Che Chuang,Yi‐Qiao Fang,Chieh‐Cheng Huang
出处
期刊:Biomaterials
[Elsevier]
日期:2021-03-24
卷期号:272: 120765-120765
被引量:38
标识
DOI:10.1016/j.biomaterials.2021.120765
摘要
Ischemic stroke, and the consequent brain cell death, is a common cause of death and disability worldwide. Current treatments that primarily aim to relieve symptoms are relatively inefficient in achieving brain tissue regeneration and functional recovery, and thus novel therapeutic options are urgently needed. Although cell-based therapies have shown promise for treating the infarcted brain, a recurring challenge is the inadequate retention and engraftment of transplanted cells at the target tissue, thereby limiting the ultimate therapeutic efficacy. Here, we show that transplantation of preassembled three-dimensional (3D) spheroids of mesenchymal stem cells (MSCs) and vascular endothelial cells (ECs) results in significantly improved cell retention and survival compared with conventional mixed-cell suspensions. The transplanted 3D spheroids exhibit notable neuroprotective, proneurogenic, proangiogenic and anti-scarring potential as evidenced by clear extracellular matrix structure formation and paracrine factor expression and secretion; this ultimately results in increased structural and motor function recovery in the brain of an ischemic stroke mouse model. Therefore, transplantation of MSCs and ECs using the 3D cell spheroid configuration not only reduces cell loss during cell harvesting/administration but also enhances the resultant therapeutic benefit, thus providing important proof-of-concept for future clinical translation.
科研通智能强力驱动
Strongly Powered by AbleSci AI